Azaya Therapeutics, Inc. Initiates Bioequivalency Study for Regulatory Approval of ATI-0918, a Liposomal Formulation of Doxorubicin Hydrochloride
10/24/2012 9:39:22 AM
SAN ANTONIO--(BUSINESS WIRE)--Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer. The test product is ATI-0918 (generic doxorubicin hydrochloride liposome injection). The reference product is doxorubicin hydrochloride (HCl) liposome injection, which is marketed in the United States, Israel and Japan as DOXIL® and in the rest of the world as CAELYX®. The U.S. Food and Drug Administration has approved this study.